ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2230

Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials

Morten Asser Karsdal1, Anne C. Bay-Jensen2, Asger Bihlet3, Peter Alexandersen4, Inger Byrjalsen3, Jeppe Andersen3, Bente J. Riis3 and Claus Christiansen3, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Center for Clinical and Basic Research, Vejle, Denmark

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Calcitonin, Clinical research, osteoarthritis and randomized trials

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Osteoarthritis - Clinical Aspects: Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a molecule based on Eligen® technology), in osteoarthritis (OA) patients with moderate to severe knee pain and joint structural damage classified as Kellgren-Lawrence 2-3.

Methods:  This is the combined reporting of two randomized, double-blind, multi-center, placebo-controlled trials (CSMC021C2301 and CSMC021C2302), evaluating the efficacy and safety of oral salmon calcitonin in patients with painful knee OA, enrolling 1,176 and 1,030 patients, respectively. The subjects had painful knee OA with structural manifestations. Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or placebo (PBO) for 24 months. The primary efficacy objectives were to examine the treatment effect compared to placebo on change over 24 months in joint space width (JSW) in the signal knee measured by X-ray, and to examine the change in pain and function using the WOMAC questionnaire. Other study parameters included patient and physician global assessment, cartilage volume measured by MRI technology, and biochemical markers of bone resorption (CTX-I) and cartilage degradation (CTX-II). The primary safety objective was to characterize the safety and tolerability profile based on adverse events incidence and changes in laboratory profiles.

Results:  At the 24 month endpoint there was no statistically significant treatment effect on JSN in any of the two studies. In CSMC021C2301 there was a statistically significant (p<0.0001) treatment effect on WOMAC (sum of pain, function, stiffness, and total scores) as well as on the biomarkers of bone and joint metabolism (p=0.0003). None of the WOMAC scores or the biomarkers achieved a statistically significant treatment effect in the CSMC021C2302 study.

Conclusion: The present formulation of oral calcitonin did not provide reproducible clinical benefits in patients with symptomatic knee OA. (NCT00486434, NCT00704847).


Disclosure:

M. A. Karsdal,

Nordic Bioscience Diagnostic,

3;

A. C. Bay-Jensen,

Nordic Bioscience Diagnostic,

1;

A. Bihlet,

Nordic Bioscience Diagnostic,

1;

P. Alexandersen,

CCBR,

3;

I. Byrjalsen,

Nordic Bioscience Diagnostic,

3;

J. Andersen,

Nordic Bioscience Diagnostic,

1;

B. J. Riis,

Nordic Bioscience Diagnostic,

1;

C. Christiansen,

Nordic Bioscience Diagnostic,

1.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-symptomatic-knee-osteoarthritis-with-oral-salmon-calcitonin-results-from-two-phase-3-randomized-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.